Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that an ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Enrollment ongoing in Phase 2 KOURAGE trial of AuxoraTM in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 ...

This week’s Edmonds City Council meeting, while short on action items, was taken up with a series of reports providing ...

St. Peter’s Community Arts Academy will honor three award recipients at its annual Dinner with the Arts event scheduled for ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

The FDA has completed its review of the investigational new drug application (IND) for PSV359, and issued a "study may proceed” letter in 1Q 2025. Site activation activities are underway, with the ...